APP下载

齐拉西酮和奥氮平治疗初诊精神分裂症患者的疗效及其对糖脂代谢的影响

2015-07-16杨学智陆冰蒙建清等

中国现代医生 2015年11期
关键词:齐拉西酮奥氮平精神分裂症

杨学智 陆冰 蒙建清等

[摘要] 目的 探讨齐拉西酮、奥氮平在初诊精神分裂症患者中的疗效比较及其对糖脂代谢的影响。 方法 选取2012年9月~2014年6月我院收治的精神分裂症初诊患者共有97例,随机分为观察组(n=49)和对照组(n=48)。观察组予齐拉西酮治疗,对照组予奥氮平治疗,比较两组的治疗疗效、对糖脂代谢的影响及不良反应。 结果观察组给予齐拉西酮治疗的总有效率为87.8%,与对照组给予奥氮平治疗的87.5%相比,差异无统计学意义(χ2=0.114,P=0.735)。治疗后,观察组的FBS、INS、HDL、LDL、TG、TC和IRI指标均显著低于对照组(t=5.715,P=0.000;t=10.969,P=0.000;t=2.276,P=0.025;t=7.756,P=0.000;t=2.713,P=0.008;t=3.906,P=0.000;t=11.814,P=0.000)。观察组、对照组嗜睡、口渴、肝功能异常、心动过速和坐立不安不良反应比较,差异无统计学意义(χ2=0.351,P=0.554;χ2=0.001,P=0.977;χ2=0.292,P=0.589;χ2=0.429,P=0.513;χ2=0.056,P=0.812)。 结论 齐拉西酮、奥氮平在初诊精神分裂症患者的治疗疗效和不良反应均相似,但齐拉西酮对糖脂代谢的影响更小,为治疗精神分裂症患者的首选。

[关键词] 精神分裂症;齐拉西酮;奥氮平;糖脂代谢

[中图分类号] R749.3 [文献标识码] A [文章编号] 1673-9701(2015)11-0016-03

[Abstract] Objective To investigate effect of ziprasidone and olanzapine in treatment of newly diagnosed schizophrenia patients and its effects on metabolism of glucose and lipid. Methods A total of 97 newly diagnosed schizophrenia patients from September 2012 to June 2014 in our hospital were selected, and were randomly divided into observation group(n=49) and control group (n=48). The observation group was given ziprasidone treatment, while the control group was given olanzapine treatment. Effects of two groups were compared. Results The total effective rate of observation group was 87.8%,while the total effective rate of control group was 87.5%,and there was no significant difference between two groups(χ2=0.114,P=0.735). After treatment, FBS, INS, HDL, LDL, TG, TC and IRI level of observation group were lower than that of control group(t=5.715, P=0.000; t=10.969,P=0.000; t=2.276,P=0.025; t=7.756,P=0.000; t=2.713,P=0.008; t=3.906,P=0.000; t=11.814,P=0.000). The sleepiness cases,thirsty cases,abnormal liver function cases, heartbeat tachycardia cases and tenterhooks cases of two groups had no significant difference (χ2=0.351,P=0.554; χ2=0.001,P=0.977; χ2=0.292,P=0.589; χ2=0.429,P=0.513; χ2=0.056,P=0.812). Conclusion Effect and adverse reactions of ziprasidone and olanzapine in the treatment of newly diagnosed schizophrenia patients are similar, but the effect of ziprasidone on glucose and lipid metabolism is smaller.

[Key words] Schizophrenia; Ziprasidone; Olanzapine; Glucose and lipid metabolism

精神分裂症为神经内科一类常见疾病,其发病原因至今仍未被查明,主要发病于青壮年时期,具有起病隐袭、病程迁延等特点。抗精神类药物目前是精神分裂症及其他各种精神病性障碍的治疗方法,但在治疗过程中容易诱发不良反应如高血脂、体重增加、高血糖等,然而由于患者在不良反应的影响下,会降低服药依从性,并提高心脑血管疾病、糖尿病等并发症的发生,影响医疗安全行为。本文为了进一步寻找一种治疗精神分裂症的有效药物,比较齐拉西酮、奥氮平在初诊患者中的治疗效果,并分析其对糖脂代谢的影响。……

登录APP查看全文

猜你喜欢

齐拉西酮奥氮平精神分裂症
食品防腐剂治疗精神分裂症,靠谱吗
护理干预在齐拉西酮治疗精神分裂症中的临床效果观察
奥氮平和氯氮平治疗精神分裂症的不良反应及药物对生活质量的影响
两种非典型抗精神病药物联合丙戊酸镁缓释片对双相躁狂发作的对照研究
精神分裂症患者采用阿立哌唑和奥氮平治疗对其糖脂代谢、不良反应发生率的影响
齐拉西酮与奥氮平治疗老年脑器质性精神障碍的疗效及对糖脂代谢的影响
齐拉西酮及心理治疗对伴抑郁症状精神分裂症患者的临床效果研究
齐拉西酮联合度洛西汀对难治性抑郁症的治疗效果观察
五行音乐疗法对慢性精神分裂症治疗作用的对照研究
脑尔新胶嚢治疗精神分裂症的初步临床观察